Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy

Show full item record



Permalink

http://hdl.handle.net/10138/217894

Citation

Vaha-Koskela , M , Tahtinen , S , Gronberg-Vaha-Koskela , S , Taipale , K , Saha , D , Merisalo-Soikkeli , M , Ahonen , M , Rouvinen-Lagerstrom , N , Hirvinen , M , Veckman , V , Matikainen , S , Zhao , F , Pakarinen , P , Salo , J , Kanerva , A , Cerullo , V & Hemminki , A 2015 , ' Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy ' , Molecular Therapy - Oncolytics , vol. 2 , 14006 . https://doi.org/10.1038/mto.2014.6

Title: Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
Author: Vaha-Koskela, Markus; Tahtinen, Siri; Gronberg-Vaha-Koskela, Susanna; Taipale, Kristian; Saha, Dipongkor; Merisalo-Soikkeli, Maiju; Ahonen, Marko; Rouvinen-Lagerstrom, Noora; Hirvinen, Mari; Veckman, Ville; Matikainen, Sampsa; Zhao, Fang; Pakarinen, Paivi; Salo, Jarmo; Kanerva, Anna; Cerullo, Vincenzo; Hemminki, Akseli
Contributor organization: Institute of Biotechnology
Haartman Institute (-2014)
Faculty of Pharmacy
Department of Obstetrics and Gynecology
Clinicum
Department of Surgery
III kirurgian klinikka
Division of Pharmaceutical Biosciences
Medicum
Drug Research Program
ImmunoViroTherapy Lab
HUS Gynecology and Obstetrics
Date: 2015-01-07
Language: eng
Number of pages: 9
Belongs to series: Molecular Therapy - Oncolytics
ISSN: 2372-7705
DOI: https://doi.org/10.1038/mto.2014.6
URI: http://hdl.handle.net/10138/217894
Abstract: Successful cancer control relies on overcoming resistance to cell death and on activation of host antitumor immunity. Oncolytic viruses are particularly attractive in this regard, as they lyse infected tumor cells and trigger robust immune responses during the infection. However, repeated injections of the same virus promote antiviral rather than antitumor immunity and tumors may mount innate antiviral defenses to restrict oncolytic virus replication. In this article, we have explored if alternating the therapy virus could circumvent these problems. We demonstrate in two virus-resistant animal models a substantial delay in antiviral immune- and innate cellular response induction by alternating injections of two immunologically distinct oncolytic viruses, adenovirus, and vaccinia virus. Our results are in support of clinical development of heterologous adeno-/vaccinia virus therapy of cancer.
Subject: SEMLIKI-FOREST-VIRUS
VACCINIA VIRUS
ONCOLYTIC ADENOVIRUS
IMMUNE-RESPONSE
GENE DELIVERY
IN-VIVO
VECTORS
CANCER
INDUCTION
PATHWAYS
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S2372770516300018_main.pdf 550.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record